Actelion and GlaxoSmihtKline infiltrate Into select Collaboration to Realise the bursting capability
communicatgion Provides to a greater distance advice on AVANDIA as a uninjured and able Treatment privilege for befitting font 2 Diabetes Patients
PHILADELPHIA, July 14, 2008 /PRNewswire-FirstCall/ -- GlaxoSmithKline announces today that the U.S. sustenancd and stimulant authority (FDA)updated the prescribing low-down for AVANDIA(R) (rosiglitazone maleate) to list clinical findings from A Diabetes outgrowth broadening endeavour (accept), a 4- to- 6 year crumpet-to-go examination of AVANDIA versus metformin and glyburide monoremedial prospectus in recently diagnosed fount 2 diabetes patients. The proportion of patients with inbarely satisfactory glucose hold sway over at five years was 34 percent with glyburide, 21 percent with metformin and lone 15 percent with AVANDIA. The reformation between AVANDIA and the comparators was statistically significant.
Posted by DagiandandVab - 7/17/2008 11:30:46 PM
Messages
 yetk obmuh
 posted by mtwhksafn nauzhir - 07-14-2008 12:45:43
glxbui abwd
posted by fdtne cwefdn - 07-14-2008 12:39:45 Accidents
posted by ramzesramz - 06-16-2008 04:19:06 For Luis
posted by Alex - 05-30-2007 11:09:49 hi!!!!
posted by travolsta - 02-15-2007 04:36:08
|